Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 immuno-bridging study of Arexvy in adults aged 60 years and older
2023-509455-13-00Phase 4Completed
- Sponsor
- GSK
- Start
- Jul 2024
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 4, randomised, single-blind trial of GSK3003899A in respiratory syncytial virus disease (RSV) (3 arms), sponsored by GSK. Primary endpoints: RSV-A neutralization immuno-bridging at 1 month and RSV-B neutralization immuno-bridging at 1 month. Started Jul 2024; status: completed.
02
Drugs
GSK3003899A
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2023-509455-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509455-13-00.